Education
About Us
Working with TipRanks
Follow Us
Ascendis Pharma (ASND)
NASDAQ:ASND
ASND Stock Chart & Stats
$201.24
-$0.55(-0.40%)
At close: 4:00 PM EST
$201.24
-$0.55(-0.40%)
Day’s Range― - ―
52-Week Range$118.03 - $223.19
Previous CloseN/A
Volume129.18K
Average Volume (3M)558.50K
Market Cap
$12.01B
Enterprise Value$12.40B
Total Cash (Recent Filing)$539.09M
Total Debt (Recent Filing)$813.65M
Price to Earnings (P/E)―
Beta0.64
Next Earnings
Feb 12, 2026EPS Estimate
-0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.17
Shares Outstanding61,151,463
10 Day Avg. Volume558,312
30 Day Avg. Volume558,502
Financial Highlights & Ratios
PEG Ratio0.86
Price to Book (P/B)-72.81
Price to Sales (P/S)21.17
P/FCF Ratio-25.02
Enterprise Value/Market Cap1.03
Enterprise Value/Revenue19.18
Enterprise Value/Gross Profit22.10
Enterprise Value/Ebitda-93.13
Forecast
1Y Price Target
$260.62Price Target Upside29.51% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)-3.81
Revenue Forecast (FY)$814.00M
Bulls Say, Bears Say
Bulls Say
Market ExpansionASND plans to submit an IND for hypochondroplasia for TransCon CNP, expanding potential market opportunities.
Product EfficacyTransCon CNP's benefits go beyond linear growth, providing strong differentiation due to its impact on skeletal proportionality, lower limb alignment, and patients' health-related quality of life.
Regulatory ProgressThe FDA has indicated no plan to convene an advisory committee meeting for TransCon CNP, which can be seen as a positive sign.
Bears Say
Conflict Of InterestThe report notes a potential conflict of interest, as Wedbush Securities does business with companies it covers, which could affect the objectivity of the report.
Market CompetitionVoxzogo from BioMarin is already available for the same indication as TransCon CNP, presenting competition in the market.
Regulatory DelayA three-month PDUFA date extension for TransCon CNP was announced, which was unexpected by both analysts and company management.
Ascendis Pharma News
ASND FAQ
What was Ascendis Pharma’s price range in the past 12 months?
Ascendis Pharma lowest stock price was $118.03 and its highest was $223.19 in the past 12 months.
What is Ascendis Pharma’s market cap?
Ascendis Pharma’s market cap is $12.01B.
When is Ascendis Pharma’s upcoming earnings report date?
Ascendis Pharma’s upcoming earnings report date is Feb 12, 2026 which is in 62 days.
How were Ascendis Pharma’s earnings last quarter?
Ascendis Pharma released its earnings results on Nov 12, 2025. The company reported -$1.17 earnings per share for the quarter, missing the consensus estimate of -$0.286 by -$0.885.
Is Ascendis Pharma overvalued?
According to Wall Street analysts Ascendis Pharma’s price is currently Undervalued.
Does Ascendis Pharma pay dividends?
Ascendis Pharma does not currently pay dividends.
What is Ascendis Pharma’s EPS estimate?
Ascendis Pharma’s EPS estimate is -0.11.
How many shares outstanding does Ascendis Pharma have?
Ascendis Pharma has 61,151,463 shares outstanding.
What happened to Ascendis Pharma’s price movement after its last earnings report?
Ascendis Pharma reported an EPS of -$1.17 in its last earnings report, missing expectations of -$0.286. Following the earnings report the stock price went up 3.629%.
Which hedge fund is a major shareholder of Ascendis Pharma?
Currently, no hedge funds are holding shares in ASND
Ascendis Pharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$260.62 (29.51% Upside)
$260.62 (29.51% Upside)
Blogger Sentiment
Bullish
ASND Sentiment 100%
Sector Average 68%
Sector Average 68%
Hedge Fund Trend
Decreased
By 124.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.9%
Last 30 Days ▲ 9.5%
Last 30 Days ▲ 9.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
55.19%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
11.15%
Trailing 12-Months
Company Description
Ascendis Pharma
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
ASND Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue growth and expansion in global markets for Eurvipath and Skytrofa, regulatory approvals, and a positive operating profit. However, challenges remain with the conversion rate for insurance approvals and increased SG&A expenses due to commercial expansion. Foreign currency impacts also affected revenue growth.View all ASND earnings summariesASND Stock 12 Month Forecast
Average Price Target
$260.62
▲(29.51% Upside)
Technical Analysis
BioMarin Pharmaceutical
―
Exelixis
―
Madrigal Pharmaceuticals
―
United Therapeutics
―
BridgeBio Pharma
―
Ownership Overview
―
Insiders
31.40% Mutual Funds
22.81% Other Institutional Investors
44.16% Public Companies and Individual Investors